TSPT: CNCE (OUTPERFORM,$34.00 PT): Aclaris Reports Results from Phase II Study in Alopecia Areata; JAK Inhibitors as a Class Continue to Demonstrate Effect

New alert via PocketInfo for TSPT:

CNCE (OUTPERFORM,$34.00 PT): Aclaris Reports Results from Phase II Study in Alopecia Areata; JAK Inhibitors as a Class Continue to Demonstrate Effect

Press Releases: http://ir.transcept.com/releases.cfm
SEC Filings: http://ir.transcept.com/sec.cfm
Stock News Alerts by Pocket Info - the app
Our free iPhone and iPad app lets you choose just the tickers you care about from over 2000 US companies and get alerts to your screen
https://itunes.apple.com/sg/app/stock-news-alerts/id708293183?mt=8